Analyst Price Targets — MBX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 9, 2026 12:57 pm | Srikripa Devarakonda | Truist Financial | $50.00 | $28.78 | StreetInsider | Truist Securities Reiterates Buy Rating on MBX Biosciences Inc (MBX) |
| January 27, 2026 9:26 pm | — | Barclays | $66.00 | $36.07 | TheFly | MBX Biosciences initiated with an Overweight at Barclays |
| January 16, 2026 11:33 am | Seamus Fernandez | Guggenheim | $88.00 | $40.91 | StreetInsider | MBX Biosciences Inc (MBX) PT Raised to $88 at Guggenheim |
| January 7, 2026 5:44 am | Michael Yee | UBS | $60.00 | $28.70 | StreetInsider | UBS Starts MBX Biosciences Inc (MBX) at Buy |
| December 19, 2025 12:48 pm | Annabel Samimy | Stifel Nicolaus | $50.00 | $28.67 | TheFly | MBX Biosciences price target raised to $50 from $45 at Stifel |
| December 4, 2025 11:53 am | — | Goldman Sachs | $18.00 | $33.94 | TheFly | MBX Biosciences initiated with a Sell at Goldman Sachs |
| August 5, 2025 9:26 am | — | Mizuho Securities | $38.00 | $11.95 | TheFly | MBX Biosciences initiated with an Outperform at Mizuho |
| October 8, 2024 5:08 am | Seamus Fernandez | Guggenheim | $44.00 | $24.20 | TheFly | MBX Biosciences initiated with a Buy at Guggenheim |
Latest News for MBX
MISSISSAUGA, ON / ACCESS Newswire / April 16, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the 2026 Bloom Burton & Co. Healthcare Investor Conference (the "Conference") taking place at the Metro Toronto Convention Centre, North Building, on April 21 and 22, 2026. The Conference provides…
Immune Therapeutics (OTCMKTS:IMUN - Get Free Report) and MBX Biosciences (NASDAQ: MBX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Earnings and Valuation This table compares Immune
CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the issuance of an equity inducement award to Karen Basbaum in connection with her commencement of employment as the…
The president & CEO of MBX Biosciences reported the acquisition of 18,500 indirectly held shares for about $526,000 on March 13, 2026. The indirect holdings (486,777 shares) are maintained via the P.
Shares of MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and ten have assigned a buy rating to the company. The average
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MBX.
U.S. House Trading
No House trades found for MBX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.